NLRP3 and Hepatic steatosis: These results suggest that the inhibitory effects of MED on hepatic steatosis are associated with the suppression of the inflammatory response through the downregulations of the iNOS-COX-2 pathway, the NLRP3 inflammasome pathway, and the expression of inflammatory cytokines.